Solventum Corp SOLV
Solventum Corp (NYSE: SOLV) is a drug developer. Its lead program is at an undisclosed stage.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 5, 2026approval Solventum received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, bringing together two advanced wound care technologies.
Received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy, bringing together two advanced wound care technologies and demonstrating continued progress integrating Acera Surgical's technology into Solventum's Advanced Wound Care portfolio.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.